Funding
Series A · Biotech

Gilgamesh Pharma raises $60m Series A for neuroscience drugs

Satori Neuro and Prime Movers Lab participated in the financing.

Updated Oct 16, 2026By RoundOS Funding desk

Gilgamesh Pharma raised $60 million in Series A financing on March 24, with participation from Satori Neuro and Prime Movers Lab. The company develops chemical entities for psychiatric and neurological disorders.

Funding history

Series A · This round$60M

Sources

  1. Gilgamesh Pharmaprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related